{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:16:23Z","timestamp":1791357383693,"version":"4.3.1"},"update-to":[{"DOI":"10.1002\/14651858.cd003026.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2009,1,21]],"date-time":"2009-01-21T00:00:00Z","timestamp":1232496000000}}],"reference-count":39,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003026.pub3","type":"journal-article","created":{"date-parts":[[2009,2,3]],"date-time":"2009-02-03T15:58:34Z","timestamp":1233676714000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment for amphetamine psychosis"],"prefix":"10.1002","author":[{"given":"Steven J","family":"Shoptaw","sequence":"first","affiliation":[{"name":"University of California; Department of Family Medicine; 10880 Wilshire Boulevard, Suite 540 Los Angeles CA USA 90024"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen","family":"Kao","sequence":"additional","affiliation":[{"name":"University of California; Department of Family Medicine; 10880 Wilshire Boulevard, Suite 540 Los Angeles CA USA 90024"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Ling","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine at UCLA; Integrated Substance abuse Programs, Department of Psychiatry and Biobehavioral Sciences; 11075 Santa Monica Blvd., Ste. 200 Los Angeles California USA CA 90025"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"key":"10.1002\/14651858.CD003026.pub3-BIB0001|cit1","first-page":"43","article-title":"A 4-week, double-blind comparison of olanzapine with haloperidol in the treatment of amphetamine psychosis","volume":"88 Suppl 3","author":"Leelahanaj","year":"2005","journal-title":"Journal of the Medical Association of Thailand"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1192\/bjp.188.5.439","article-title":"Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: Randomised controlled trial","volume":"188","author":"Baker","year":"2006","journal-title":"British Journal of Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD003026.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/10550490490512834","article-title":"Quantitative drug levels in stimulant psychosis: relationship to symptom severity, catecholamines and hyperkinesia","volume":"13","author":"Batki","year":"2004","journal-title":"American Journal on Addictions"},{"issue":"4","key":"10.1002\/14651858.CD003026.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S0893-133X(98)00126-2","article-title":"Effects of atypical antipsychotic drug treatment on amphetamine-induced striatal dopamine release in patients with psychotic disorders","volume":"20","author":"Breier","year":"1999","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD003026.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/01.jcp.0000085412.08426.08","article-title":"Cocaine and amphetamine use in patients with psychiatric illness: a randomised trial of typical antipsychotic continuation or discontinuation","volume":"23","author":"Brown","year":"2003","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD003026.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajmg.b.30187","article-title":"Morbid risk for psychiatric disorder among the relatives of methamphetamine users with and without psychosis","volume":"136","author":"Chen","year":"2005","journal-title":"American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00063110-199709000-00003","article-title":"Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone","volume":"4","author":"Richards","year":"1997","journal-title":"European Journal of Emergency Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003026.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1017\/S1461145703003675","article-title":"Psychotic symptoms in methamphetamine psychotic in-patients","volume":"6","author":"Srisurapanont","year":"2003","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1196\/annals.1369.012","article-title":"Longitudinal clinical course following pharmacological treatment of methamphetamine psychosis which persists after long-term abstinence","volume":"1074","author":"Akiyama","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02246016","article-title":"The biological, social and clinical bases of drug addiction: commentary and debate","volume":"125","author":"Altman","year":"1996","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1176\/ajp.131.7.817","article-title":"The antagonism of amphetamine-induced symptomatology by a neuroleptic","volume":"131","author":"Angrist","year":"1974","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD003026.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.neuro.2004.06.003","article-title":"The neurotoxic effects of 3, 4-methylenedioxymethamphetamine (MDMA) and methamphetamine on serotonin, dopamine, and GABA-ergic terminals: an in-vitro autoradiographic study in rats","volume":"25","author":"Armstrong","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(65)91033-0","article-title":"Influence of urinary pH on excretion of amphetamine","volume":"1","author":"Beckett","year":"1965","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003026.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/01.yco.0000218594.46431.2f","article-title":"Insights from recent positron emission tomographic studies of drug abuse and dependence","volume":"19","author":"Chang","year":"2006","journal-title":"Current Opinion in Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD003026.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/j.1440-1665.2006.02252.x","article-title":"Drug-induced psychosis associated with crystalline methamphetamine","volume":"14","author":"Dore","year":"2006","journal-title":"Australasian Psychiatry"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0016|cit16","first-page":"248","article-title":"Dependence on amphetamine, cocaine, and other stimulants","volume-title":"Drug abuse: clinical and basic concepts","author":"Ellinwood Jr","year":"1977"},{"issue":"7","key":"10.1002\/14651858.CD003026.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1046\/j.1360-0443.2002.00195.x","article-title":"Methamphetamine: drug use and psychoses becomes a major public health issue in the Asia Pacific region","volume":"97","author":"Farrell","year":"2002","journal-title":"Addiction"},{"issue":"10","key":"10.1002\/14651858.CD003026.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2967\/jnumed.107.040279","article-title":"PET studies of d-methamphetamine pharmacokinetics in primates: comparison with l-methamphetamine and (-)-cocaine","volume":"48","author":"Fowler","year":"2007","journal-title":"Journal of Nuclear Medicine"},{"issue":"2","key":"10.1002\/14651858.CD003026.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1176\/jnp.14.2.239-a","article-title":"Risk factors for treatment-resistive methamphetamine psychosis","volume":"14","author":"Fujii","year":"2002","journal-title":"Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"336","DOI":"10.5694\/j.1326-5377.2007.tb00932.x","article-title":"Amphetamine-related presentations to an inner-city tertiary emergency department: A prospective evaluation","volume":"186","author":"Gray","year":"2007","journal-title":"Medical Journal of Australia"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0021|cit21","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006] The Cochrane Library, Issue 4, 2006. Chichester, UK: John Wiley & Sons, Ltd."},{"key":"10.1002\/14651858.CD003026.pub3-BIB0022|cit22","volume-title":"A handbook on drug and alcohol abuse: the biomedical aspects","author":"Hofmann","year":"1983"},{"issue":"8","key":"10.1002\/14651858.CD003026.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1176\/appi.ajp.162.8.1461","article-title":"Effects of methamphetamine dependence and HIV infection on cerebral morphology","volume":"162","author":"Jernigan","year":"2005","journal-title":"American Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD003026.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.biopsych.2007.04.031","article-title":"Anterior cingulate cortex and benefit of predictive cueing on response inhibition in stimulant dependent individuals","volume":"63","author":"Leland","year":"2008","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD003026.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0920-9964(98)00105-4","article-title":"Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomised controlled trials","volume":"35","author":"Leucht","year":"1999","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD003026.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1007\/BF03405613","article-title":"Methamphetamine use among marginalized youth in British Columbia","volume":"97","author":"Martin","year":"2006","journal-title":"Canadian Journal of Public Health"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0027|cit27","unstructured":"McIver C McGregor C Baigent M Spain D Newcombe D Ali R Guidelines for the medical management of patients with methamphetamine-induced psychosis Drug and Alcohol Services: South Australia 2006"},{"issue":"10","key":"10.1002\/14651858.CD003026.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1111\/j.1360-0443.2006.01496.x","article-title":"The prevalence of psychotic symptoms among methamphetamine users","volume":"101","author":"McKetin","year":"2006","journal-title":"Addiction"},{"issue":"3","key":"10.1002\/14651858.CD003026.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/10673220591003605","article-title":"Implications of chronic methamphetamine use: a literature review","volume":"13","author":"Meredith","year":"2005","journal-title":"Harvard Review of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD003026.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0893-133X(01)00334-7","article-title":"Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects","volume":"26","author":"Paulus","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD003026.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1093\/schbul\/18.1.115","article-title":"Relapse of paranoid psychotic state in methamphetamine model of schizophrenia","volume":"18","author":"Sato","year":"1992","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","article-title":"Empirical evidence of bias: dimensions of methodological quality assocaited with estimates of treatment effects in controlled trial","volume":"273","author":"Schulz","year":"1995","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/1573400054065550","article-title":"Methamphetamine psychosis: How is it related to schizophrenia, a review of the literature","volume":"1","author":"Sweeting","year":"2005","journal-title":"Current Psychiatry Review"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1196\/annals.1316.035","article-title":"Clinical features of sensitization to methamphetamine observed in patients with methamphetamine dependence and psychosis","volume":"1025","author":"Ujike","year":"2004","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"3","key":"10.1002\/14651858.CD003026.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1176\/appi.ajp.158.3.377","article-title":"Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers","volume":"158","author":"Volkow","year":"2001","journal-title":"American Journal of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD003026.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s002130050453","article-title":"Precipitating factors in spontaneous recurrence of methamphetamine psychosis","volume":"134","author":"Yui","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.2000.tb05204.x","article-title":"Susceptibility to subsequent episodes in spontaneous recurrence of methamphetamine psychosis","volume":"914","author":"Yui","year":"2000","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD003026.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1749-6632.2002.tb04171.x","article-title":"Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis","volume":"965","author":"Yui","year":"2002","journal-title":"Annals of the New York Academy of Sciences"},{"issue":"4","key":"10.1002\/14651858.CD003026.pub3-BIB0039|cit39","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003026","article-title":"Treatment from amphetamine psychosis","author":"Srisurapanont","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003026.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T21:15:08Z","timestamp":1628543708000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003026.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Drugs and Alcohol Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,1,21]]},"references-count":39,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003026.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,21]]}}}